FDA leadership transition signals continuity for supplement industry focus
The appointment of Kyle Diamantas as acting FDA Commissioner, replacing Dr. Marty Makary, suggests continued prioritisation of dietary supplement modernisation, crucial for navigating complex regulatory frameworks.
London, United Kingdom — 18 May 2026
A significant leadership change at the US Food and Drug Administration (FDA) has placed Kyle Diamantas, formerly Deputy Commissioner for Food, into the acting Commissioner role, following Dr. Marty Makary's 13-month tenure. Diamantas's background in food policy and his expressed commitment to dietary supplement modernisation signal continuity for the industry. Industry observers, including Ivan Wasserman of Amin Wasserman Gurnani LLP, suggest this appointment will ensure that supplement issues remain a high-level focus during the transition.
Diamantas previously stated that the supplement industry's substantial growth in the last three decades has outpaced its regulatory framework, indicating a strong governmental interest in updating existing guidelines. This stance suggests that US supplement manufacturers and brand owners should prepare for potential regulatory adjustments aimed at modernising the sector, which could impact product development and compliance strategies.
Concurrently, the European Food Safety Authority (EFSA) has issued a positive safety opinion for EffePharm’s β-NMN, approving a daily intake of 300 mg, excluding pregnant and lactating women. This decision is a critical step towards European Union approval, anticipated within five to seven months. Jerome Le Bloch of FoodChain ID predicts NMN will become a bestseller in the EU supplement market once approved. Currently, only EffePharm can communicate this positive opinion due to Novel Food regulations, creating a temporary market advantage for the applicant.
Separately, Suannutra USA has partnered with Fitoplancton Marino to distribute TetraSOD in the US market. TetraSOD, derived from Tetraselmis chuii microalgae, is positioned for cellular and metabolic health, offering high superoxide dismutase (SOD) activity. Anthony Weston, CEO of Suannutra, highlights TetraSOD's scientific evidence and low effective dose as key differentiators, anticipating its potential as a 'hero ingredient' given its fast-acting benefits and foundational support for physiological systems.
What this means for United Kingdom
UK brand owners must monitor the FDA's modernisation efforts as these often influence TGA and MHRA regulatory approaches, potentially demanding proactive reformulation or labelling adjustments to maintain market access. The impending EU approval of NMN presents a prime opportunity for UK manufacturers to prepare formulations and secure supply chains for a high-demand ingredient, anticipating its post-Brexit impact on the UK market. Procurement teams should evaluate TetraSOD for novel product lines targeting cellular health, leveraging Suannutra's US distribution to assess market traction and consumer acceptance before potential UK expansion, considering its clinically backed, low dose profile for competitive advantage.
Many leading brands in this category are manufactured in partnership with Supplement Factory.